Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 94.1% in March

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 15,786 shares, a growth of 94.1% from the February 26th total of 8,131 shares. Based on an average daily volume of 26,663 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.4% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a report on Wednesday, January 28th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kiora Pharmaceuticals has an average rating of “Hold” and a consensus target price of $10.00.

Kiora Pharmaceuticals Price Performance

NASDAQ KPRX traded down $0.09 on Friday, hitting $1.88. 24,776 shares of the stock were exchanged, compared to its average volume of 28,162. The company has a market capitalization of $7.43 million, a PE ratio of -0.71 and a beta of -0.80. The business’s fifty day moving average is $2.11 and its 200 day moving average is $2.24. Kiora Pharmaceuticals has a 52 week low of $1.76 and a 52 week high of $4.18.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.90). Analysts predict that Kiora Pharmaceuticals will post 1.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiora Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. bought a new stake in Kiora Pharmaceuticals in the fourth quarter valued at approximately $152,000. Two Sigma Investments LP bought a new position in shares of Kiora Pharmaceuticals during the 3rd quarter worth approximately $33,000. Renaissance Technologies LLC increased its holdings in shares of Kiora Pharmaceuticals by 71.0% during the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after acquiring an additional 8,800 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Kiora Pharmaceuticals during the 3rd quarter worth approximately $125,000. Finally, DRW Securities LLC raised its stake in Kiora Pharmaceuticals by 199.2% in the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after acquiring an additional 73,417 shares during the period. Institutional investors and hedge funds own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.